Navigation Links
Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
Date:5/6/2010

score the safety of Oramed's oral insulin preparation. These results show a positive trend of efficacy for the tested oral insulin preparation." Nadav Kidron, Chief Executive Officer of Oramed Pharmaceuticals, added "this study, as well as data from our earlier studies, suggests that Oramed's technology is an effective and well-tolerated delivery platform that will potentially make a significant clinical impact on diabetes management. We are proceeding with confidence toward IND approval in the United States."

For more information about Oramed's clinical development programs, please visit http://www.oramed.com.

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual res
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
2. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
3. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
4. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
5. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
6. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
7. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
8. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
10. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 OMICS Group’s 5th ... during 18-20 August, 2014 at Double Tree by Hilton ... recent developments in Analytical & Bioanalytical research methods only ... Speaking on this occasion, Dr. Srinubabu Gedela, MD of ... conference is a remarkable one in bringing a unique ...
(Date:7/10/2014)... Senior supply chain management executives from over 50 ... of “Reducing Cost, Lead Time, & Defects in the ... the partnership of the Bio Supply Management Alliance ( ... SCMI) of the University of San Diego in ... Institute of Peace and Justice in San Diego, Devendra ...
(Date:7/10/2014)... ST. PETERSBURG, Russia , July 10, 2014 /PRNewswire/ ... the Russian Federation Dmitry Medvedev , presented ... a biopharmaceutical company BIOCAD . The Company is ... the scope of MabNext project BIOCAD develops a number ... of cancer and autoimmune diseases. The ceremony took place ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... 2011  AMPAC Fine Chemicals LLC (AFC), ... announced it has concluded an agreement with Chimerix, Inc. ... the API in Chimerix,s broad spectrum antiviral drug candidate, ... treatment of smallpox.  Chimerix will provide the investigational drug ...
... Neurologix, Inc. (OTCBB: NRGX), a biotechnology company ... of the brain and central nervous system, today announced its ... 30, 2011. For the three months ended June ... million, as compared with a net loss of approximately $4.5 ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that ... Life Sciences Management Access Conference at the Le Parker Meridien ... presentation is scheduled for Wednesday, Aug. 17 at 3:35 p.m. ...   Interleukin,s management team will be available for ...
Cached Biology Technology:AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 2AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 3AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API 4Neurologix Announces Second Quarter 2011 Financial Results 2Neurologix Announces Second Quarter 2011 Financial Results 3Neurologix Announces Second Quarter 2011 Financial Results 4Neurologix Announces Second Quarter 2011 Financial Results 5Neurologix Announces Second Quarter 2011 Financial Results 6Neurologix Announces Second Quarter 2011 Financial Results 7Neurologix Announces Second Quarter 2011 Financial Results 8Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2
(Date:7/10/2014)... cities in New Mexico, nearly every public golf course ... precious potable water supplies. Across the U.S. Southwest as ... receive treated effluent. Reusing the effluent increases the sustainability ... homeowners alike fertilize their lawns during the growing season. ... Mexico State University turfgrass expert has a new vision ...
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2
... the bugs. The rates of drug-resistant bacteria infecting patients ... increasing steadily in recent years, according to two new ... Diseases, now available online. , Drug resistance in microorganisms ... prescribing and overuse of antibiotics. These drug-resistant "superbugs" can ...
... a healthy dose of fat, suggests a new study published ... directly from the diet or generated from sugars spark a ... blood levels of sugar, cholesterol, and other fats, according to ... those critical metabolic pathways in motion, they found. The findings ...
... lung damage, according to a team of scientists who used ... in lung transplant patients. , Reporting in today's edition of ... University of Texas Medical School at Houston, and colleagues at ... than 1 percent of a certain type of reparative lung ...
Cached Biology News:Two studies document rise of superbugs in the environment 2Two studies document rise of superbugs in the environment 3Fat's fate depends on its source 2Circulating stem cells play small role in lung repair 2Circulating stem cells play small role in lung repair 3
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
RABBIT ANTI HUMAN ATR (aa2122-2380) Immunogen: Human ATR peptide, amino acids 2122-2380...
RABBIT ANTI D-TYROSINE CONJUGATE...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: